Loren Miller, MD, MPH
Investigator, The Lundquist Institute
Associate Chief, Division of Infectious Diseases, Department of Medicine, Harbor-UCLA Medical Center
Professor of Medicine, David Geffen School of Medicine at UCLA
Contact
Email
Community-Associated MRSA Infections; MRSA, Skin and Urinary Tract Infections; Health Services Research - Infectious Diseases
Research Description
Loren Gregory Miller, MD, MPH is a Professor of Medicine at the David Geffen School of Medicine at University of California, Los Angeles. Dr. Miller also is the Associate Chief in the Division of Adult Infectious Diseases at Harbor-UCLA Medical Center in addition to his role as an investigator at LA BioMed. He has completed fellowships in Infectious Diseases and Health Services Research. His research has focused on:1. Epidemiology, treatment, and prevention of methicillin resistant Staphylococcus aureus (MRSA) and community associated MRSA (CA-MRSA) infections, especially skin and soft tissue infections.
2. Epidemiology and outcomes of other common infectious diseases, including primary data collection, analysis of large databases, decision analysis, cost-effective analyses, meta-analysis, and agent based modeling.
3. Health services research approaches to studying delivery of care to patients with suspected or documented infectious diseases.
Theme Groups
Research Interests
Education
- MD, 1992, Columbia University of Physicians and Surgeons, New York, NY
Recent and/or Significant Publications
Miller LG, Daum RS, Creech CB, Downing MD, Eells SJ, Pettibone S, Hoagland RJ, Chambers HF. Clindamycin versus Trimethoprim-Sulfamethoxazole for Uncomplicated Skin Infections. New England Journal of Medicine 2015; 372:1093-103.
Miller LG, Eisenberg DF, Liu H, Chang CL, Wang Y, Luthra R, Wallace A, Fang C, Singer J, Suaya JA. Incidence of skin and soft tissue infections in ambulatory and inpatient settings, 2005-2010. BMC Infectious Diseases, 2015:15:362.
Eells SJ, Nguyen M, Jung J, Macias-Gil R, May L, Miller LG. The Relationship Between Adherence to Oral Antibiotics and Post-Discharge Clinical Outcomes Among Patients Hospitalized with Staphylococcus aureus Skin Infections. Antimicrobial Agents and Chemotherapy 2016; 60: 2941-8.
McKinnell JA, Kunz DF, Moser SA, Vangala S, Tseng C-H, Shapiro M, Miller LG. Patient-level analysis of incident vancomycin resistant Enterococci colonization and antibiotic days of therapy. Epidemiology and Infection 2016;144:1748-55.
Johnson JR, Johnston B, Thuras P, Launer B, Sokurenko EV, Miller LG. Escherichia coli Sequence Type 131 H30 Is the Main Driver of Emerging Extended-Spectrum-β-Lactamase-Producing E. coli at a Tertiary Care Center. mSphere 2016; 1:pii: e00314-16.
Videos
Loren Miller MD Discusses Ebola on American Health Journal